GELA and Celgene Announce Collaboration to Evaluate Potential ofREVLIMID for Major Study in Follicular Lymphoma

Groupe d'Etude des Lymphomes de l'Adulte and Celgene International Sarl CELG today announced a collaboration to conduct an international randomized study to evaluate the therapeutic potential of the REVLIMID (lenalidomide)/rituximab combination regimen in patients with newly diagnosed follicular lymphoma . The RELEVANCE Study looks to advance the treatment of patients diagnosed with FL, a form of non-Hodgkin's lymphoma. FL represents the second most common lymphoma, with approximately 25,000 new cases diagnosed per year in the US and Europe. The clinical benefits of REVLIMID, as a single agent and in combination with rituximab, continue to be reported in peer-reviewed publications and at major international medical meetings, including the 11th Annual ICML.